<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:canf="http://canfite.com/20260630"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="canf-20260630.xsd" xlink:type="simple"/>
    <context id="cref_2094213010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_623090204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:DefinitiveAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1680085804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:ADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:DefinitiveAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-02</instant>
        </period>
    </context>
    <context id="cref_1196691303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:NewWarrantSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:ADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:DefinitiveAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-02</instant>
        </period>
    </context>
    <context id="cref_1544386629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:ADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:DefinitiveAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_295900952">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:ADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:DefinitiveAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_331617260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:ADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:DefinitiveAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-02</instant>
        </period>
    </context>
    <context id="cref_938686948">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2047077658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">canf:SpecialGeneralMeetingOfShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-10</startDate>
            <endDate>2025-11-10</endDate>
        </period>
    </context>
    <context id="cref_2045841882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_865548389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March302026AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_564029540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March302026AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1198272088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March302026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_522442402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March302026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1824311542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:JulyTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_574636523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:JulyTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_208007257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:AprilTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1279906403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:AprilTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1601656141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2024AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_160109638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2024AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1512099602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:AugustTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_531699999">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:AugustTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1147646893">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:November2023AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1903003350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:November2023AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_385622006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:NovemberTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1746235067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:NovemberTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_782394268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2023AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_506140291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2023AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_378139949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1859850197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="canf:StatementOfIncomeLocationsBalanceAxis">canf:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_2122251663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="canf:StatementOfIncomeLocationsBalanceAxis">canf:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1643494283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="canf:StatementOfIncomeLocationsBalanceAxis">canf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1976580826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="canf:StatementOfIncomeLocationsBalanceAxis">canf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1557615935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_727317909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1961366856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_452638574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_145758306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1354944142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_913146987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_830861461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">canf:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_784624382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">canf:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="cref_1997173082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">canf:TwoThousandThirteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-11-28</instant>
        </period>
    </context>
    <context id="cref_702949829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:InducementLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_194033335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1181267821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2113885254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_922156503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:InducementLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1402186821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2023622756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:InducementLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_859234007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-07-29</endDate>
        </period>
    </context>
    <context id="cref_1592729201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-04</instant>
        </period>
    </context>
    <context id="cref_1143956495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2026-06-04</instant>
        </period>
    </context>
    <context id="cref_1384122139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2026-06-04</startDate>
            <endDate>2026-06-04</endDate>
        </period>
    </context>
    <context id="cref_884744515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">canf:RegulatoryAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2068542187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">canf:PhaseIIIStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_723484537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">canf:PhaseIIStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1057463331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">canf:PhaseIStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1139639759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1510215796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_24478589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_532028027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1339819970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1273714876">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_148376220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1133730023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_165518910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1254216181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_708622080">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1930495210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1156932951">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_600411129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_912825080">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_309435350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_336050472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_409840626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_202246652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_26548218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_507776425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_852029009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1321253939">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1740129667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2120532623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_940291136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_720239079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_144499886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1498443796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1125609332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1849091748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_420295115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_2119775611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_926761789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_311222658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1961081762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_374364333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-29</instant>
        </period>
    </context>
    <context id="cref_1183359736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_199092052">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <unit id="uref_623090204">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="uref_1680085804">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="uref_1196691303">
        <measure>shares</measure>
    </unit>
    <unit id="uref_1394700569">
        <measure>pure</measure>
    </unit>
    <unit id="uref_884744515">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:DocumentPeriodEndDate contextRef="cref_2094213010" id="ixv-338">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="cref_2094213010" id="ixv-339">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="cref_2094213010" id="ixv-340">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="cref_2094213010" id="ixv-341">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="cref_2094213010" id="ixv-342">0001536196</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="cref_2094213010" id="ixv-1111">6-K</dei:DocumentType>
    <dei:DocumentFiscalYearFocus contextRef="cref_2094213010" id="ixv-1112">2026</dei:DocumentFiscalYearFocus>
    <dei:EntityFileNumber contextRef="cref_2094213010" id="ixv-1113">001-36203</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="cref_2094213010" id="ixv-1114">CAN-FITE BIOPHARMA LTD.</dei:EntityRegistrantName>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_1498443796"
      id="fc_125167420"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_311222658"
      id="fc_311222658"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_1125609332"
      id="fc_638248903"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1498443796"
      id="fc_399826672"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_311222658"
      id="fc_2114211164"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1125609332"
      id="fc_1463987508"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1498443796"
      id="fc_388210144"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <canf:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired
      contextRef="cref_2094213010"
      id="fc_1595376583"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="cref_1557615935"
      id="fc_409101"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="cref_1557615935"
      id="fc_541373389"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_144499886"
      id="fc_278868211"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_311222658"
      id="fc_382687809"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1961366856"
      id="fc_1618594030"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1557615935"
      id="fc_1501636071"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_309435350"
      id="fc_254025928"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_409840626"
      id="fc_1507442036"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_1961081762"
      id="fc_1961081762"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_202246652"
      id="fc_1526346197"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_409840626"
      id="fc_284679322"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1961081762"
      id="fc_659933444"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_202246652"
      id="fc_1638807315"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <canf:NumberOfShares
      contextRef="cref_374364333"
      decimals="0"
      id="fc_374364333"
      unitRef="uref_1196691303">2</canf:NumberOfShares>
    <us-gaap:StockholdersEquity
      contextRef="cref_926761789"
      id="fc_1693552383"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="cref_1143956495"
      id="fc_1998992026"
      unitRef="uref_1680085804"
      xsi:nil="true"/>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageDateFairValue
      contextRef="cref_1961366856"
      id="fc_1526868192"
      unitRef="uref_1680085804"
      xsi:nil="true"/>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageDateFairValue
      contextRef="cref_1557615935"
      id="fc_588479102"
      unitRef="uref_1680085804"
      xsi:nil="true"/>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageOfTheGrantDateFairValueVestedAndExpectedToVest
      contextRef="cref_1557615935"
      id="fc_901828697"
      unitRef="uref_1680085804"
      xsi:nil="true"/>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageOfTheGrantDateFairValueExercisable
      contextRef="cref_1557615935"
      id="fc_2144920386"
      unitRef="uref_1680085804"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_409840626"
      id="fc_1642803509"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_336050472"
      id="fc_863337818"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1961081762"
      id="fc_616360652"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_720239079"
      id="fc_1706754029"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_1133730023"
      id="fc_624621150"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_1183359736"
      id="fc_1183359736"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_1339819970"
      id="fc_1488941706"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_199092052"
      id="fc_199092052"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="cref_1557615935"
      id="fc_834248409"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="cref_1961366856"
      id="fc_1166882705"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1557615935"
      id="fc_1829850252"
      unitRef="uref_1680085804"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_1557615935"
      id="fc_2038929731"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_1961366856"
      id="fc_1829243923"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_2094213010"
      id="fc_218618044"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_2094213010"
      id="fc_2032534524"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1961366856"
      id="fc_1703023224"
      unitRef="uref_1680085804"
      xsi:nil="true"/>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent
      contextRef="cref_1961366856"
      id="fc_944124040"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent
      contextRef="cref_1557615935"
      id="fc_742488695"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_1321253939"
      id="fc_1197433180"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="cref_148376220"
      id="fc_1574302654"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="cref_199092052"
      id="fc_1876010762"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1254216181"
      id="fc_1686291502"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1183359736"
      id="fc_1347708674"
      unitRef="uref_623090204"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5178"
      unitRef="uref_623090204">2985000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5179"
      unitRef="uref_623090204">5528000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5180"
      unitRef="uref_623090204">4052000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5181"
      unitRef="uref_623090204">3011000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5182"
      unitRef="uref_623090204">960000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5183"
      unitRef="uref_623090204">900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5184"
      unitRef="uref_623090204">6000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5185"
      unitRef="uref_623090204">1000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsCurrent
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5186"
      unitRef="uref_623090204">8003000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5187"
      unitRef="uref_623090204">9440000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5188"
      unitRef="uref_623090204">47000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5189"
      unitRef="uref_623090204">69000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5190"
      unitRef="uref_623090204">5000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5191"
      unitRef="uref_623090204">5000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5192"
      unitRef="uref_623090204">52000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5193"
      unitRef="uref_623090204">74000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5194"
      unitRef="uref_623090204">8055000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5195"
      unitRef="uref_623090204">9514000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5196"
      unitRef="uref_623090204">681000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5197"
      unitRef="uref_623090204">1161000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5198"
      unitRef="uref_623090204">48000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5199"
      unitRef="uref_623090204">56000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5200"
      unitRef="uref_623090204">405000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5201"
      unitRef="uref_623090204">405000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5202"
      unitRef="uref_623090204">1091000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5203"
      unitRef="uref_623090204">1109000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5204"
      unitRef="uref_623090204">2225000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5205"
      unitRef="uref_623090204">2731000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5206"
      unitRef="uref_623090204">1000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5207"
      unitRef="uref_623090204">15000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5208"
      unitRef="uref_623090204">974000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5209"
      unitRef="uref_623090204">1176000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5210"
      unitRef="uref_623090204">975000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5211"
      unitRef="uref_623090204">1191000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1557615935"
      decimals="0"
      id="fc_1469520299"
      unitRef="uref_1196691303">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1961366856"
      decimals="0"
      id="ixv-5213"
      unitRef="uref_1196691303">14000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1557615935"
      decimals="0"
      id="fc_1069285458"
      unitRef="uref_1196691303">4285093</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1557615935"
      decimals="0"
      id="fc_1921622472"
      unitRef="uref_1196691303">4285093</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1961366856"
      decimals="0"
      id="ixv-5216"
      unitRef="uref_1196691303">2618425</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1961366856"
      decimals="0"
      id="ixv-5217"
      unitRef="uref_1196691303">2618425</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5218"
      unitRef="uref_623090204">184518000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5219"
      unitRef="uref_623090204">180654000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5220"
      unitRef="uref_623090204">1127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5221"
      unitRef="uref_623090204">1127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5222"
      unitRef="uref_623090204">-180790000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5223"
      unitRef="uref_623090204">-176189000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5224"
      unitRef="uref_623090204">4855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5225"
      unitRef="uref_623090204">5592000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5226"
      unitRef="uref_623090204">8055000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5227"
      unitRef="uref_623090204">9514000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5228"
      unitRef="uref_623090204">202000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5229"
      unitRef="uref_623090204">202000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5230"
      unitRef="uref_623090204">3456000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5231"
      unitRef="uref_623090204">3034000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5232"
      unitRef="uref_623090204">1426000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5233"
      unitRef="uref_623090204">2066000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5234"
      unitRef="uref_623090204">-4680000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5235"
      unitRef="uref_623090204">-4898000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5236"
      unitRef="uref_623090204">79000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5237"
      unitRef="uref_623090204">22000</us-gaap:InvestmentIncomeNet>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5238"
      unitRef="uref_623090204">-4601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5239"
      unitRef="uref_623090204">-4876000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_2094213010"
      decimals="2"
      id="fc_1491930199"
      unitRef="uref_1680085804">-1.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_2094213010"
      decimals="2"
      id="ixv-5241"
      unitRef="uref_1680085804">-1.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_378139949"
      decimals="2"
      id="ixv-5242"
      unitRef="uref_1680085804">-4.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_378139949"
      decimals="2"
      id="ixv-5243"
      unitRef="uref_1680085804">-4.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_2094213010"
      decimals="0"
      id="fc_485659790"
      unitRef="uref_1196691303">3711018</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_2094213010"
      decimals="0"
      id="fc_40832969"
      unitRef="uref_1196691303">3711018</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_378139949"
      decimals="0"
      id="fc_624161538"
      unitRef="uref_1196691303">1137303</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_378139949"
      decimals="0"
      id="fc_1439374755"
      unitRef="uref_1196691303">1137303</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="cref_926761789"
      decimals="0"
      id="ixv-5249"
      unitRef="uref_1196691303">2618425</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_2119775611"
      decimals="-3"
      id="ixv-5250"
      unitRef="uref_623090204">180654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_420295115"
      decimals="-3"
      id="ixv-5251"
      unitRef="uref_623090204">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1849091748"
      decimals="-3"
      id="ixv-5252"
      unitRef="uref_623090204">-176189000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5253"
      unitRef="uref_623090204">5592000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1125609332"
      decimals="-3"
      id="ixv-5254"
      unitRef="uref_623090204">-4601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5255"
      unitRef="uref_623090204">-4601000</us-gaap:NetIncomeLoss>
    <canf:NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5256"
      unitRef="uref_623090204">558000</canf:NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="cref_1498443796"
      decimals="0"
      id="ixv-5257"
      unitRef="uref_1196691303">1666668</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_144499886"
      decimals="-3"
      id="ixv-5258"
      unitRef="uref_623090204">3772000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5259"
      unitRef="uref_623090204">3772000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_144499886"
      decimals="-3"
      id="ixv-5260"
      unitRef="uref_623090204">92000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5261"
      unitRef="uref_623090204">92000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:SharesOutstanding
      contextRef="cref_720239079"
      decimals="0"
      id="ixv-5262"
      unitRef="uref_1196691303">4285093</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_940291136"
      decimals="-3"
      id="ixv-5263"
      unitRef="uref_623090204">184518000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_2120532623"
      decimals="-3"
      id="ixv-5264"
      unitRef="uref_623090204">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1740129667"
      decimals="-3"
      id="ixv-5265"
      unitRef="uref_623090204">-180790000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5266"
      unitRef="uref_623090204">4855000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_1321253939"
      decimals="0"
      id="fc_1321253939"
      unitRef="uref_1196691303">994394</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_852029009"
      decimals="-3"
      id="fc_852029009"
      unitRef="uref_623090204">170670000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_507776425"
      decimals="-3"
      id="fc_507776425"
      unitRef="uref_623090204">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_26548218"
      decimals="-3"
      id="fc_26548218"
      unitRef="uref_623090204">-166361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1930495210"
      decimals="-3"
      id="fc_1575155540"
      unitRef="uref_623090204">5436000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="cref_202246652"
      decimals="-3"
      id="ixv-5272"
      unitRef="uref_623090204">-4876000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5273"
      unitRef="uref_623090204">-4876000</us-gaap:NetIncomeLoss>
    <canf:NetOfIssuanceCostsOfOrdinarySharesAndWarrants
      contextRef="cref_378139949"
      decimals="-3"
      id="fc_317108046"
      unitRef="uref_623090204">452000</canf:NetOfIssuanceCostsOfOrdinarySharesAndWarrants>
    <canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants
      contextRef="cref_409840626"
      decimals="0"
      id="fc_117223515"
      unitRef="uref_1196691303">250000</canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="cref_336050472"
      decimals="-3"
      id="fc_1313348637"
      unitRef="uref_623090204">2548000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="cref_378139949"
      decimals="-3"
      id="fc_1802582590"
      unitRef="uref_623090204">2548000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:NetOfIssuanceCostsOrdinarySharesDueToATM
      contextRef="cref_378139949"
      decimals="-3"
      id="fc_1080289311"
      unitRef="uref_623090204">170000</canf:NetOfIssuanceCostsOrdinarySharesDueToATM>
    <canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM
      contextRef="cref_409840626"
      decimals="0"
      id="fc_1036898106"
      unitRef="uref_1196691303">68075</canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_336050472"
      decimals="-3"
      id="fc_464583565"
      unitRef="uref_623090204">825000</canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_378139949"
      decimals="-3"
      id="fc_1845223154"
      unitRef="uref_623090204">825000</canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="cref_409840626"
      decimals="0"
      id="fc_409840626"
      unitRef="uref_1196691303">10000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_336050472"
      decimals="-3"
      id="fc_336050472"
      unitRef="uref_623090204">251000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_378139949"
      decimals="-3"
      id="fc_40836862"
      unitRef="uref_623090204">251000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:SharesOutstanding
      contextRef="cref_309435350"
      decimals="0"
      id="fc_309435350"
      unitRef="uref_1196691303">1322469</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_912825080"
      decimals="-3"
      id="fc_912825080"
      unitRef="uref_623090204">174294000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_600411129"
      decimals="-3"
      id="fc_600411129"
      unitRef="uref_623090204">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1156932951"
      decimals="-3"
      id="fc_1156932951"
      unitRef="uref_623090204">-171237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_708622080"
      decimals="-3"
      id="fc_1977624787"
      unitRef="uref_623090204">4184000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5291"
      unitRef="uref_623090204">-4601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5292"
      unitRef="uref_623090204">-4876000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5293"
      unitRef="uref_623090204">1000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5294"
      unitRef="uref_623090204">23000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5295"
      unitRef="uref_623090204">22000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5296"
      unitRef="uref_623090204">20000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5297"
      unitRef="uref_623090204">92000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5298"
      unitRef="uref_623090204">251000</us-gaap:ShareBasedCompensation>
    <canf:ChangesInFairValueOfShortTermInvestment
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5299"
      unitRef="uref_623090204">-5000</canf:ChangesInFairValueOfShortTermInvestment>
    <canf:ChangesInFairValueOfShortTermInvestment
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5300"
      unitRef="uref_623090204">3000</canf:ChangesInFairValueOfShortTermInvestment>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="cref_2094213010"
      decimals="-3"
      id="fc_1092252419"
      unitRef="uref_623090204">41000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5302"
      unitRef="uref_623090204">-48000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5303"
      unitRef="uref_623090204">60000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5304"
      unitRef="uref_623090204">73000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5305"
      unitRef="uref_623090204">-22000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5306"
      unitRef="uref_623090204">-14000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5307"
      unitRef="uref_623090204">-480000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5308"
      unitRef="uref_623090204">534000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5309"
      unitRef="uref_623090204">-202000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5310"
      unitRef="uref_623090204">-198000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5311"
      unitRef="uref_623090204">-18000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5312"
      unitRef="uref_623090204">-470000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5313"
      unitRef="uref_623090204">-5314000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5314"
      unitRef="uref_623090204">-4752000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5315"
      unitRef="uref_623090204">1000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5316"
      unitRef="uref_623090204">1000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5317"
      unitRef="uref_623090204">1000000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5318"
      unitRef="uref_623090204">-3000000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5319"
      unitRef="uref_623090204">-1001000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5320"
      unitRef="uref_623090204">2999000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5321"
      unitRef="uref_623090204">825000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <canf:ProceedsFromIssuanceOfOrdinarySharesNetOfIssuanceCosts
      contextRef="cref_2094213010"
      decimals="-3"
      id="fc_496779035"
      unitRef="uref_623090204">3772000</canf:ProceedsFromIssuanceOfOrdinarySharesNetOfIssuanceCosts>
    <canf:ProceedsFromIssuanceOfOrdinarySharesNetOfIssuanceCosts
      contextRef="cref_378139949"
      decimals="-3"
      id="fc_533656076"
      unitRef="uref_623090204">2548000</canf:ProceedsFromIssuanceOfOrdinarySharesNetOfIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5324"
      unitRef="uref_623090204">3772000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5325"
      unitRef="uref_623090204">3373000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5326"
      unitRef="uref_623090204">9000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5327"
      unitRef="uref_623090204">-2543000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5328"
      unitRef="uref_623090204">1629000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5329"
      unitRef="uref_623090204">5528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1930495210"
      decimals="-3"
      id="ixv-5330"
      unitRef="uref_623090204">4825000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5331"
      unitRef="uref_623090204">2985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_708622080"
      decimals="-3"
      id="ixv-5332"
      unitRef="uref_623090204">6454000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="cref_2094213010" id="ixv-3790">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.75in; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE&#160;1:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;GENERAL&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;a.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Can-Fite Biopharma Ltd. (the &#x201c;Company&#x201d;) was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. The Company&#x2019;s pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators at the A3AR.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt; The Company&#x2019;s ordinary shares have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#x201c;CFBI&#x201d; and the Company&#x2019;s American Depositary Shares (&#x201c;ADSs&#x201d;) began public trading on the over the counter market in the U.S. in October 2012 and since November 2013 the Company&#x2019;s ADSs have been publicly traded on the NYSE American under the symbol &#x201c;CANF&#x201d;. Each ADS represents 2 ordinary shares of the Company. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;b.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Under&#160;Accounting Standard Codification (&#x201c;ASC&#x201d;)&#160;Subtopic 205-40,&#160;Presentation of Financial Statements&#x2014;Going Concern&#160;(&#x201c;ASC 205-40&#x201d;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its obligations as they become due within one year after the date that the financial statements are issued. As required under ASC 205-40, management&#x2019;s evaluation should initially not take into consideration the potential mitigating effects of management&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;i&gt;Evaluation of Substantial Doubt Raised&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white;"&gt;In performing the first step of the evaluation, the Company concluded that the following conditions raised substantial doubt about its ability to continue as a going concern:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -0.25in; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif;"&gt;History of net losses of&#160;$ 4,601 and $ 4,876 for the Six months ended June 30, 2026 and 2025, respectively.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -0.25in; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif;"&gt;Net operating cash outflow of&#160;$5,314 and $4,752&#160;for the Six months ended June 30, 2026 and 2025, respectively.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -0.25in; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif;"&gt;Reliance on additional financing in order to execute its research and development plans.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;&lt;i&gt;Consideration&#160;of Management&#x2019;s Plans&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt; In performing the second step of this assessment, the Company is required to evaluate whether it is probable that the Company&#x2019;s plans will be effectively implemented within one year after the financial statements are issued and whether it is probable those plans will alleviate the substantial doubt raised about the Company&#x2019;s ability to continue as a going concern. As of June 30, 2026, the Company had $7,037&#160;available cash and cash equivalents. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;The Company has approved a plan, to improve its available cash balances, liquidity and cash flows generated from operations. The Company is prepared to implement the following actions as required by business and market conditions: reducing non-essential expenses to conserve cash and improve its liquidity position, deferral and reprioritization of certain research and development programs that would involve reduced program spend until additional financing will be obtained in order to strengthen liquidity and to preserve key research and development, commercial and functional roles.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;/span&gt;&lt;/p&gt;            &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white;"&gt;Management Assessment of Ability to Continue as a Going Concern&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white;"&gt;The Company has a history of operating losses and negative cash flows from operations. However, despite these conditions, the Company believes management&#x2019;s plans, as described more fully above, will provide sufficient liquidity to meet its financial obligations.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white;"&gt;Therefore, management concluded these plans alleviate the substantial doubt that was raised about the Company&#x2019;s ability to continue as a going concern for at least twelve months from the date that the consolidated financial statements were issued.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white;"&gt;Future Plans and Considerations&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;Although not considered for purposes of the Company&#x2019;s assessment of whether substantial doubt was alleviated, the Company has plans to improve operating cash flows by entering into strategic partnerships with other companies that can provide access to additional customers and new markets. The Company may also seek to raise additional funds through the issuance of debt and/or equity securities or otherwise.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;The Company&#x2019;s plans are subject to inherent risks and uncertainties. Accordingly, there can be no assurance that the Company&#x2019;s plans can be effectively implemented and, therefore, that the conditions can be effectively mitigated.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;Until such time, if ever, that the Company can generate revenue sufficient to achieve profitability, the Company expects to finance its operations through equity or debt financings, which may not be available to the Company on the timing needed or on terms that the Company deems to be favorable. To the extent that the Company raises additional capital through the sale of equity or debt securities, the ownership interest of its stockholders will be diluted. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;c.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Basis of Presentation:&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white;"&gt;These unaudited Condensed consolidated financial statements have been prepared as of June 30, 2026 and for the six months period then ended. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These unaudited Condensed consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes of the Company for the year ended December 31, 2025 that are included in the Company&#x2019;s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 26, 2026 (the &#x201c;Annual Report on Form 20-F&#x201d;). The results of operations presented are not necessarily indicative of the results to be expected for the year ending December 31, 2026.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <canf:NumberOfOrdinaryShares
      contextRef="cref_1557615935"
      decimals="0"
      id="ixv-5333"
      unitRef="uref_1196691303">2</canf:NumberOfOrdinaryShares>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5334"
      unitRef="uref_623090204">-4601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5335"
      unitRef="uref_623090204">-4876000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5336"
      unitRef="uref_623090204">-5314000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5337"
      unitRef="uref_623090204">-4752000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5338"
      unitRef="uref_623090204">7037000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="cref_2094213010" id="ixv-3920">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.75in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE&#160;2:- &lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;d.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Revenue Recognition &#x2013; Contract Balances&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt; Contract liabilities include amounts received from customers for which revenue has not yet been recognized. Contract liabilities amounted to $1,379&#160;and $1,581&#160;as of June 30, 2026 and December 31, 2025, respectively and are presented under deferred revenues. During the Six-month period ended June 30, 2026, the Company recognized revenues in the amount of $202&#160;which have been included in the contract liabilities at December&#160;31, 2025. &lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="cref_2094213010" id="ixv-3931">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;d.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Revenue Recognition &#x2013; Contract Balances&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt; Contract liabilities include amounts received from customers for which revenue has not yet been recognized. Contract liabilities amounted to $1,379&#160;and $1,581&#160;as of June 30, 2026 and December 31, 2025, respectively and are presented under deferred revenues. During the Six-month period ended June 30, 2026, the Company recognized revenues in the amount of $202&#160;which have been included in the contract liabilities at December&#160;31, 2025. &lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="cref_1557615935"
      decimals="-3"
      id="ixv-5339"
      unitRef="uref_623090204">1379000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="cref_1961366856"
      decimals="-3"
      id="ixv-5340"
      unitRef="uref_623090204">1581000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5341"
      unitRef="uref_623090204">202000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="cref_2094213010" id="ixv-3941">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.75in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE&#160;3:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;In accordance with ASC 820 &#x201c;Fair Value Measurements and Disclosures&#x201d;, the Company measures its short-term investment at fair value. Short-term investments are classified within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. The company&#x2019;s short-term investment consists of an equity investment in a publicly traded company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;The Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates: instruments as of the following dates:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Fair value measurements&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Description&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Fair value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 1&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 3&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt;"&gt;Short term deposits&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;4,052&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_624621150;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;4,052&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1183359736;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Short-term equity investment&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;6&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;6&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1686291502;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1347708674;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;December 31, 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Fair value measurements&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Description&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Fair value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 1&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 3&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt;"&gt;Short term deposits&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;3,011&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1488941706;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;3,011&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_199092052;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Short-term equity investment&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1574302654;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1876010762;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="cref_2094213010" id="ixv-3954">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;The Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates: instruments as of the following dates:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Fair value measurements&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Description&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Fair value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 1&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 3&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt;"&gt;Short term deposits&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;4,052&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_624621150;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;4,052&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1183359736;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Short-term equity investment&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;6&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;6&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1686291502;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1347708674;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;December 31, 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Fair value measurements&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Description&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Fair value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 1&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 3&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt;"&gt;Short term deposits&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;3,011&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1488941706;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;3,011&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_199092052;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Short-term equity investment&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1574302654;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1876010762;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_165518910"
      decimals="-3"
      id="ixv-5342"
      unitRef="uref_623090204">4052000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_1254216181"
      decimals="-3"
      id="ixv-5343"
      unitRef="uref_623090204">4052000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="cref_165518910"
      decimals="-3"
      id="ixv-5344"
      unitRef="uref_623090204">6000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1133730023"
      decimals="-3"
      id="ixv-5345"
      unitRef="uref_623090204">6000</us-gaap:ShortTermInvestments>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_1273714876"
      decimals="-3"
      id="ixv-5346"
      unitRef="uref_623090204">3011000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_148376220"
      decimals="-3"
      id="ixv-5347"
      unitRef="uref_623090204">3011000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1273714876"
      decimals="-3"
      id="ixv-5348"
      unitRef="uref_623090204">1000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1339819970"
      decimals="-3"
      id="ixv-5349"
      unitRef="uref_623090204">1000</us-gaap:ShortTermInvestments>
    <us-gaap:EarningsPerShareTextBlock contextRef="cref_2094213010" id="ixv-4134">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.75in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE&#160;4:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;EARNING PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;Basic and diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each period. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#x201c;Earnings per Share&#x201d;.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;The following table sets forth the computation of basic and diluted net loss per share for the periods presented:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Six months ended June 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Numerator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;Net loss applicable to shareholders of Ordinary Shares&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(4,601&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(4,876&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -9pt; padding-left: 9pt;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -9pt; padding-left: 9pt;"&gt;Denominator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;Weighted average shares used in computing basic and diluted net loss per share (*)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,711,018&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,137,303&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;Net loss per share of Ordinary Share, basic and diluted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1.24&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;(4.29&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(*)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Retroactively adjusted to give effect to the reverse share split, see also note 6.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;All outstanding share options and warrants (except for prefunded warrants) for the period ended June 30, 2026 and 2025 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;The potential shares of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Six months ended June 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-indent: -9pt; padding-left: 9pt;"&gt;Options&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;204,465&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;49,600&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -9pt; padding-left: 9pt;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt;"&gt;Warrants&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;4,228,828&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;890,542&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -9pt; padding-left: 9pt;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;4,433,293&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;940,142&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="cref_2094213010" id="ixv-4147">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;The following table sets forth the computation of basic and diluted net loss per share for the periods presented:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Six months ended June 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Numerator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;Net loss applicable to shareholders of Ordinary Shares&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(4,601&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(4,876&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -9pt; padding-left: 9pt;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -9pt; padding-left: 9pt;"&gt;Denominator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;Weighted average shares used in computing basic and diluted net loss per share (*)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,711,018&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,137,303&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;Net loss per share of Ordinary Share, basic and diluted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1.24&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;(4.29&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(*)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Retroactively adjusted to give effect to the reverse share split, see also note 6.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5350"
      unitRef="uref_623090204">-4601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5351"
      unitRef="uref_623090204">-4876000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_2094213010"
      decimals="0"
      id="fc_159356048"
      unitRef="uref_1196691303">3711018</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_2094213010"
      decimals="0"
      id="fc_1307329754"
      unitRef="uref_1196691303">3711018</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_378139949"
      decimals="0"
      id="fc_1789321536"
      unitRef="uref_1196691303">1137303</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_378139949"
      decimals="0"
      id="fc_709383207"
      unitRef="uref_1196691303">1137303</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_2094213010"
      decimals="2"
      id="ixv-5356"
      unitRef="uref_1680085804">-1.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_2094213010"
      decimals="2"
      id="ixv-5357"
      unitRef="uref_1680085804">-1.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_378139949"
      decimals="2"
      id="ixv-5358"
      unitRef="uref_1680085804">-4.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_378139949"
      decimals="2"
      id="ixv-5359"
      unitRef="uref_1680085804">-4.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="cref_2094213010" id="ixv-4250">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;The potential shares of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Six months ended June 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-indent: -9pt; padding-left: 9pt;"&gt;Options&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;204,465&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;49,600&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -9pt; padding-left: 9pt;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt;"&gt;Warrants&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;4,228,828&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;890,542&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -9pt; padding-left: 9pt;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;4,433,293&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;940,142&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_532028027"
      decimals="0"
      id="ixv-5361"
      unitRef="uref_1196691303">204465</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_24478589"
      decimals="0"
      id="ixv-5362"
      unitRef="uref_1196691303">49600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1510215796"
      decimals="0"
      id="ixv-5363"
      unitRef="uref_1196691303">4228828</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1139639759"
      decimals="0"
      id="ixv-5364"
      unitRef="uref_1196691303">890542</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_2094213010"
      decimals="0"
      id="ixv-5365"
      unitRef="uref_1196691303">4433293</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_378139949"
      decimals="0"
      id="ixv-5366"
      unitRef="uref_1196691303">940142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="cref_2094213010" id="ixv-4342">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.75in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE&#160;5:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 89%; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;CONTINGENT LIABILITIES AND COMMITMENTS&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt;The Company is committed to pay royalties as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;a.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;A one-time concession commission of &#x20ac;25&#160;thousand;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;b.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Annual royalties of &#x20ac;10&#160;thousand until the clinical trials commence;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;c.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;2%-3% of net sales (as defined in the agreement) received by the Company;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;d.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Royalties in a total amount of up to &#x20ac;850&#160;thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#x20ac;50 thousand upon initiation of Phase I studies; (ii) &#x20ac;100 thousand upon initiation of Phase II studies; (iii) &#x20ac;200 thousand upon initiation of Phase III studies; and (iv) &#x20ac;500 thousand upon marketing approval by any regulatory authority.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;e.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of&#160;10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify;"&gt; As of June 30, 2026 and December 31, 2025, &lt;span style="-sec-ix-hidden:fc_944124040;"&gt;&lt;span style="-sec-ix-hidden:fc_742488695;"&gt;no&lt;/span&gt;&lt;/span&gt; material accrual has been recorded with respect to Leiden University. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:NoninterestExpenseCommissionExpense
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5367"
      unitRef="uref_884744515">25000</us-gaap:NoninterestExpenseCommissionExpense>
    <us-gaap:RoyaltyExpense
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5368"
      unitRef="uref_884744515">10000</us-gaap:RoyaltyExpense>
    <canf:PercentageOfNetSales
      contextRef="cref_913146987"
      decimals="2"
      id="ixv-5369"
      unitRef="uref_1394700569">0.02</canf:PercentageOfNetSales>
    <canf:PercentageOfNetSales
      contextRef="cref_1354944142"
      decimals="2"
      id="ixv-5370"
      unitRef="uref_1394700569">0.03</canf:PercentageOfNetSales>
    <us-gaap:RoyaltyExpense
      contextRef="cref_1354944142"
      decimals="-3"
      id="ixv-5371"
      unitRef="uref_884744515">850000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="cref_1057463331"
      decimals="-3"
      id="ixv-5372"
      unitRef="uref_884744515">50000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="cref_723484537"
      decimals="-3"
      id="ixv-5373"
      unitRef="uref_884744515">100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="cref_2068542187"
      decimals="-3"
      id="ixv-5374"
      unitRef="uref_884744515">200000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="cref_884744515"
      decimals="-3"
      id="ixv-5375"
      unitRef="uref_884744515">500000</us-gaap:RoyaltyExpense>
    <canf:RoyaltyPaymentsPercentage
      contextRef="cref_2094213010"
      decimals="2"
      id="ixv-5376"
      unitRef="uref_1394700569">0.10</canf:RoyaltyPaymentsPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="cref_2094213010" id="ixv-4396">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.75in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE&#160;6:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 89%; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.75in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;1.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;All ordinary shares have equal rights for all intent and purposes and each ordinary share confers its holder:&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 1in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;a.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;The right to be invited and participate in all the Company&#x2019;s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company&#x2019;s general meeting participated.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 1in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;b.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 1in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;c.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;The right to participate in the distribution of the Company&#x2019;s assets upon liquidation.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.75in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;2.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;On June 4, 2026, our shareholders increased our authorized share capital by 16,000,000 shares, such that our authorized share capital is equal to 30,000,000 shares, with &lt;span style="-sec-ix-hidden:fc_1998992026;"&gt;no&lt;/span&gt; par value&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in;"&gt;&lt;/p&gt;            &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.75in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;3.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Issuance of ordinary shares and warrants:&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify;"&gt; On March 4, 2026, the Company entered into an inducement offer letter agreement (the &#x201c;Inducement Letter&#x201d;) with a certain holder (the &#x201c;Holder&#x201d;) of certain of the Company&#x2019;s existing warrants to purchase up to 795,869 of the Company&#x2019;s American Depositary Shares (&#x201c;ADS&#x201d;), each ADS representing &lt;span style="-sec-ix-hidden:fc_374364333;"&gt;two&lt;/span&gt; ordinary shares, no par value, issued on July 29, 2025 at an exercise price of&#160;$9.34 per ADS (the &#x201c;Existing Warrants&#x201d;). &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify;"&gt; Pursuant to the Inducement Letter, the Holder agreed to exercise for cash its Existing Warrants to purchase an aggregate of 795,869 of the Company&#x2019;s ADSs at a reduced exercise price of $5.00 per ADS in consideration of the Company&#x2019;s agreement to issue new warrants to purchase ADSs (the &#x201c;New Warrants&#x201d;), as described below, to purchase up to an aggregate of 1,591,738 ADSs (the &#x201c;New Warrant Shares&#x201d;), at an exercise price of $5.00 per ADS. The Company received aggregate gross proceeds of $4.0 million from the exercise of the Existing Warrants by the Holder, before deducting placement agent fees and other offering expenses payable by the Company. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify;"&gt; The transaction was accounted for as a modification of the existing warrants under ASC 815-40. Since the existing warrants and the new warrants qualified for equity classification before and after the transaction, the incremental fair value resulting from the modification, amounting to $133, was recorded as an equity issuance cost. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify;"&gt; The Company also agreed to pay the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds received from the Holder&#x2019;s exercise of the Existing Warrants, as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the Existing Warrants. The Company has also agreed to issue to the placement agent to purchase up to 55,711 ADSs which will have the same terms as the New Warrants except that the Placement Agent Warrants will have an exercise price equal to $6.25 per ADS. Similar to the New Warrants, the Placement Agent Warrants will be immediately exercisable from the date of issuance until the two year anniversary of the effective date of the resale registration statement. In addition, the Company has also agreed to pay the placement agent $91 for other fees. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify;"&gt; As part of the Inducement letter, the Company also received gross proceeds of approximately $350 following the exercise of 37,465 Existing Warrants. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.75in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;4.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Share options plan:&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify;"&gt; On November 28, 2013, the board of directors approved the adoption of the 2013 Share Option Plan (the &#x201c;2013 Plan&#x201d;). Under the Company&#x2019;s 2013 Plan, in May 2023, the Company&#x2019;s Board of Directors approved to increase number of ordinary shares reserved for issuance to 28,333. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify;"&gt; On August 30, 2023, the Company&#x2019;s board of directors approved the adoption on a new 2023 Share Option Plan (the &#x201c;2023 Plan&#x201d;). The Company has 203,333 shares reserved for issuance under the 2023 Plan. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify;"&gt; Under the Company&#x2019;s Plans, the Company may grant its officers, directors, employees and consultants, share options. Each share option granted shall be exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will be granted with a term in excess of 10 years. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify;"&gt; As of June 30, 2026, 23,686 shares are available for future grant under the Company&#x2019;s 2023 Plans. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify;"&gt;&lt;/p&gt;            &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;The fair value of the Company&#x2019;s share options granted was estimated using the binomial option pricing model using the following range assumptions:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Description&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;Six months ended &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.93&#160;&#x2013;&#160;3.67&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;87.10-&#160;92.72&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 89%; text-align: left;"&gt;Dividend yield&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Contractual life&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;Early Exercise Multiple (Suboptimal Factor)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2.5&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;Exercise price (NIS)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5.94-6.77&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;The following table summarizes the Company&#x2019;s options activity during the Six months ended June 30, 2026:&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Number of options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; terms (in&lt;br/&gt; years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;Aggregate&lt;/p&gt; &lt;p style="margin-top: 0; margin-bottom: 0;"&gt;intrinsic &lt;br/&gt; value&lt;/p&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;weighted&lt;br/&gt; average of the&lt;br/&gt; grant date&lt;br/&gt;  fair value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 40%;"&gt;Outstanding at December 31, 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;49,533&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;87.31&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;6.6&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1618594030;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1526868192;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;Grants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;155,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;2.11&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&#160;&#160;&#160;-&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.00&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Expired&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(68&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;4,479&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1595376583;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 4pt;"&gt;Outstanding at June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;204,465&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;23.10&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;9.0&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1501636071;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_588479102;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Vested and expected to vest at June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;204,465&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;23.10&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;9.0&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_409101;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_901828697;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;Exercisable at June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;35,104&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;111.13&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;6.7&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_541373389;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2144920386;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;/p&gt;            &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;Share based expenses recognized in the financial statements:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Six months ended June 30&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Research and development&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;36&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;30&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;General and administrative (*)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;56&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;221&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;92&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;251&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.75in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;5.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Warrants to purchase ordinary share:&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white;"&gt;The following table summarizes information regarding outstanding warrants to purchase the Company&#x2019;s ordinary shares as of June 30, 2026:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Issuance date&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Number of &lt;br/&gt; outstanding&lt;br/&gt; Warrants&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Exercise &lt;br/&gt; price per &lt;br/&gt; warrant&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: justify;"&gt;January 2023 agent&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;9,545&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;68.75&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;November 2023&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;243,377&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;17.50&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify;"&gt;November 2023 agent&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13,746&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;19.13&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;August 2024&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;571,429&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;22.50&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify;"&gt;August 2024 agent&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;20,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;21.90&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;April 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;17,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;15.0&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify;"&gt;July 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;58,333&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.50&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;March 30 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,183,476&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;2.50&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;March 30 2026 agent&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;111,422&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;3.13&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;4,228,828&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&lt;/p&gt;            &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.75in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;6.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Share split:&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white;"&gt; On November 10, 2025, a Special General Meeting of Shareholders of the Company approved a reverse split at a ratio of 1:3,000. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white;"&gt; Concurrently with the reverse split, the Company effected a corresponding change in the ratio of ordinary shares underlying each of the Company&#x2019;s American Depositary Shares (ADSs), such that its ratio of ADSs to ordinary shares will change from one (1) ADS representing three hundred (300) ordinary shares to a new ratio of one (1) ADS representing two (2) ordinary shares and no adjustment will be made to the outstanding number of the ADSs of the Company. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white;"&gt;For accounting purposes, all share and per share amounts for ordinary shares, preferred shares, warrants, options and loss per share amounts have been adjusted to give retroactive effect to the forward and reverse share splits for all periods presented in these financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white;"&gt;Any fractional shares of more than one-half of one whole share that resulted from the reverse share splits have been rounded up to the nearest whole share.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights contextRef="cref_2094213010" id="ixv-5377">one</us-gaap:CommonStockVotingRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1384122139"
      decimals="0"
      id="ixv-5378"
      unitRef="uref_1196691303">16000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1143956495"
      decimals="0"
      id="ixv-5379"
      unitRef="uref_1196691303">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1592729201"
      decimals="0"
      id="ixv-5380"
      unitRef="uref_1196691303">795869</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="cref_859234007"
      decimals="2"
      id="ixv-5381"
      unitRef="uref_1680085804">9.34</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_2023622756"
      decimals="0"
      id="ixv-5382"
      unitRef="uref_1196691303">795869</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_2023622756"
      decimals="2"
      id="ixv-5383"
      unitRef="uref_1680085804">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1402186821"
      decimals="0"
      id="ixv-5384"
      unitRef="uref_1196691303">1591738</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1402186821"
      decimals="2"
      id="ixv-5385"
      unitRef="uref_1680085804">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="cref_922156503"
      decimals="-5"
      id="ixv-5386"
      unitRef="uref_623090204">4000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="cref_2094213010"
      decimals="-3"
      id="fc_1600278583"
      unitRef="uref_623090204">133000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <canf:ClassOfWarrantOrRightPercentage
      contextRef="cref_2113885254"
      decimals="3"
      id="ixv-5388"
      unitRef="uref_1394700569">0.07</canf:ClassOfWarrantOrRightPercentage>
    <canf:PercentageOfManagementFee
      contextRef="cref_2094213010"
      decimals="3"
      id="ixv-5389"
      unitRef="uref_1394700569">0.01</canf:PercentageOfManagementFee>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1181267821"
      decimals="0"
      id="ixv-5390"
      unitRef="uref_1196691303">55711</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="cref_2094213010"
      decimals="2"
      id="ixv-5391"
      unitRef="uref_1680085804">6.25</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:OtherUnderwritingExpense
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5392"
      unitRef="uref_623090204">91000</us-gaap:OtherUnderwritingExpense>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="cref_194033335"
      decimals="-3"
      id="fc_194033335"
      unitRef="uref_623090204">350000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_702949829"
      decimals="0"
      id="ixv-5394"
      unitRef="uref_1196691303">37465</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1997173082"
      decimals="0"
      id="ixv-5395"
      unitRef="uref_1196691303">28333</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_784624382"
      decimals="0"
      id="ixv-5396"
      unitRef="uref_1196691303">203333</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <canf:GrantedExcessYears contextRef="cref_1557615935" id="ixv-5397">P10Y</canf:GrantedExcessYears>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_830861461"
      decimals="0"
      id="ixv-5398"
      unitRef="uref_1196691303">23686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="cref_2094213010" id="ixv-4528">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;The fair value of the Company&#x2019;s share options granted was estimated using the binomial option pricing model using the following range assumptions:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Description&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;Six months ended &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.93&#160;&#x2013;&#160;3.67&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;87.10-&#160;92.72&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 89%; text-align: left;"&gt;Dividend yield&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Contractual life&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;Early Exercise Multiple (Suboptimal Factor)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2.5&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;Exercise price (NIS)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5.94-6.77&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_913146987"
      decimals="4"
      id="ixv-5399"
      unitRef="uref_1394700569">0.0393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1354944142"
      decimals="4"
      id="ixv-5400"
      unitRef="uref_1394700569">0.0367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_913146987"
      decimals="4"
      id="ixv-5401"
      unitRef="uref_1394700569">0.871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1354944142"
      decimals="4"
      id="ixv-5402"
      unitRef="uref_1394700569">0.9272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_2094213010"
      decimals="2"
      id="ixv-5403"
      unitRef="uref_1394700569">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_2094213010" id="ixv-5404">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
      contextRef="cref_2094213010"
      decimals="3"
      id="ixv-5405"
      unitRef="uref_1394700569">0.025</canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="cref_145758306"
      decimals="2"
      id="ixv-5406"
      unitRef="uref_1680085804">5.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="cref_452638574"
      decimals="2"
      id="ixv-5407"
      unitRef="uref_1680085804">6.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="cref_2094213010" id="ixv-4576">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;The following table summarizes the Company&#x2019;s options activity during the Six months ended June 30, 2026:&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Number of options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; terms (in&lt;br/&gt; years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;Aggregate&lt;/p&gt; &lt;p style="margin-top: 0; margin-bottom: 0;"&gt;intrinsic &lt;br/&gt; value&lt;/p&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;weighted&lt;br/&gt; average of the&lt;br/&gt; grant date&lt;br/&gt;  fair value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 40%;"&gt;Outstanding at December 31, 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;49,533&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;87.31&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;6.6&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1618594030;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1526868192;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;Grants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;155,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;2.11&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&#160;&#160;&#160;-&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.00&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Expired&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(68&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;4,479&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1595376583;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 4pt;"&gt;Outstanding at June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;204,465&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;23.10&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;9.0&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1501636071;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_588479102;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Vested and expected to vest at June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;204,465&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;23.10&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;9.0&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_409101;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_901828697;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;Exercisable at June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;35,104&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;111.13&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;6.7&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_541373389;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2144920386;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1961366856"
      decimals="0"
      id="ixv-5408"
      unitRef="uref_1196691303">49533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1961366856"
      decimals="2"
      id="ixv-5409"
      unitRef="uref_1680085804">87.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_727317909" id="ixv-5410">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_2094213010"
      decimals="0"
      id="ixv-5411"
      unitRef="uref_1196691303">155000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="cref_2094213010"
      decimals="2"
      id="ixv-5412"
      unitRef="uref_1680085804">2.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <canf:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants contextRef="cref_2094213010" id="ixv-5413">P10Y</canf:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageOfTheGrantDateFairValueGrants
      contextRef="cref_2094213010"
      decimals="2"
      id="ixv-5414"
      unitRef="uref_1680085804">0</canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageOfTheGrantDateFairValueGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="cref_2094213010"
      decimals="0"
      id="ixv-5415"
      unitRef="uref_1196691303">68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="cref_2094213010"
      decimals="0"
      id="ixv-5416"
      unitRef="uref_1680085804">4479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1557615935"
      decimals="0"
      id="ixv-5417"
      unitRef="uref_1196691303">204465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1557615935"
      decimals="2"
      id="ixv-5418"
      unitRef="uref_1680085804">23.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_2094213010" id="ixv-5419">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="cref_1557615935"
      decimals="0"
      id="ixv-5420"
      unitRef="uref_1196691303">204465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="cref_1557615935"
      decimals="2"
      id="ixv-5421"
      unitRef="uref_1680085804">23.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="cref_2094213010" id="ixv-5422">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="cref_1557615935"
      decimals="0"
      id="ixv-5423"
      unitRef="uref_1196691303">35104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1557615935"
      decimals="2"
      id="ixv-5424"
      unitRef="uref_1680085804">111.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="cref_2094213010" id="ixv-5425">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="cref_2094213010" id="ixv-4863">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify;"&gt;Share based expenses recognized in the financial statements:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Six months ended June 30&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Research and development&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;36&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;30&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;General and administrative (*)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;56&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;221&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;92&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;251&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1976580826"
      decimals="-3"
      id="ixv-5426"
      unitRef="uref_623090204">36000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1643494283"
      decimals="-3"
      id="ixv-5427"
      unitRef="uref_623090204">30000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_2122251663"
      decimals="-3"
      id="ixv-5428"
      unitRef="uref_623090204">56000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1859850197"
      decimals="-3"
      id="ixv-5429"
      unitRef="uref_623090204">221000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_2094213010"
      decimals="-3"
      id="ixv-5430"
      unitRef="uref_623090204">92000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_378139949"
      decimals="-3"
      id="ixv-5431"
      unitRef="uref_623090204">251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="cref_2094213010" id="ixv-4937">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white;"&gt;The following table summarizes information regarding outstanding warrants to purchase the Company&#x2019;s ordinary shares as of June 30, 2026:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Issuance date&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Number of &lt;br/&gt; outstanding&lt;br/&gt; Warrants&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Exercise &lt;br/&gt; price per &lt;br/&gt; warrant&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: justify;"&gt;January 2023 agent&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;9,545&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;68.75&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;November 2023&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;243,377&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;17.50&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify;"&gt;November 2023 agent&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13,746&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;19.13&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;August 2024&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;571,429&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;22.50&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify;"&gt;August 2024 agent&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;20,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;21.90&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;April 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;17,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;15.0&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify;"&gt;July 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;58,333&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.50&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;March 30 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,183,476&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;2.50&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;March 30 2026 agent&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;111,422&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;3.13&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;4,228,828&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <canf:IssuanceDate contextRef="cref_506140291" id="ixv-5432">January 2023 agent</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_782394268"
      decimals="0"
      id="ixv-5433"
      unitRef="uref_1196691303">9545</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_782394268"
      decimals="2"
      id="ixv-5434"
      unitRef="uref_1680085804">68.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_1746235067" id="ixv-5435">November 2023</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_385622006"
      decimals="0"
      id="ixv-5436"
      unitRef="uref_1196691303">243377</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_385622006"
      decimals="2"
      id="ixv-5437"
      unitRef="uref_1680085804">17.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_1903003350" id="ixv-5438">November 2023 agent</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1147646893"
      decimals="0"
      id="ixv-5439"
      unitRef="uref_1196691303">13746</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1147646893"
      decimals="2"
      id="ixv-5440"
      unitRef="uref_1680085804">19.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_531699999" id="ixv-5441">August 2024</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1512099602"
      decimals="0"
      id="ixv-5442"
      unitRef="uref_1196691303">571429</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1512099602"
      decimals="2"
      id="ixv-5443"
      unitRef="uref_1680085804">22.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_160109638" id="ixv-5444">August 2024 agent</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1601656141"
      decimals="0"
      id="ixv-5445"
      unitRef="uref_1196691303">20000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1601656141"
      decimals="2"
      id="ixv-5446"
      unitRef="uref_1680085804">21.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_1279906403" id="ixv-5447">April 2025</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_208007257"
      decimals="0"
      id="ixv-5448"
      unitRef="uref_1196691303">17500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_208007257"
      decimals="1"
      id="ixv-5449"
      unitRef="uref_1680085804">15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_574636523" id="ixv-5450">July 2025</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1824311542"
      decimals="0"
      id="ixv-5451"
      unitRef="uref_1196691303">58333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1824311542"
      decimals="2"
      id="ixv-5452"
      unitRef="uref_1680085804">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_522442402" id="ixv-5453">March 30 2026</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1198272088"
      decimals="0"
      id="ixv-5454"
      unitRef="uref_1196691303">3183476</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1198272088"
      decimals="2"
      id="ixv-5455"
      unitRef="uref_1680085804">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_564029540" id="ixv-5456">March 30 2026 agent</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_865548389"
      decimals="0"
      id="ixv-5457"
      unitRef="uref_1196691303">111422</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_865548389"
      decimals="2"
      id="ixv-5458"
      unitRef="uref_1680085804">3.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_2045841882"
      decimals="0"
      id="ixv-5459"
      unitRef="uref_1196691303">4228828</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="cref_2047077658" id="ixv-5460">1:3,000</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="cref_938686948"
      decimals="0"
      id="ixv-5461"
      unitRef="uref_1196691303">300</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="cref_2094213010"
      decimals="0"
      id="ixv-5462"
      unitRef="uref_1196691303">2</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:SubsequentEventsTextBlock contextRef="cref_2094213010" id="ixv-5104">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.75in; font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE&#160;7:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 89%; text-align: justify; font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white;"&gt; On September 2, 2026, the Company announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 ADSs, having an exercise price of $5.00 per ADS, issued in March 2026, at a reduced exercise price of $2.50 per ADS. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white;"&gt; In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase up to 3,183,476 ADSs. The new warrants will have an exercise price of $2.50 per ADS, will be immediately exercisable until the twenty-four month anniversary of the effective date of the Resale Registration Statement. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white;"&gt; The gross proceeds from the exercise of the warrants were approximately $4,000, prior to deducting placement agent fees and offering expenses.&#160; &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_331617260"
      decimals="0"
      id="fc_331617260"
      unitRef="uref_1196691303">1591738</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_295900952"
      decimals="2"
      id="ixv-5464"
      unitRef="uref_1680085804">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1544386629"
      decimals="2"
      id="ixv-5465"
      unitRef="uref_1680085804">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="cref_1196691303"
      decimals="0"
      id="fc_1196691303"
      unitRef="uref_1196691303">3183476</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1680085804"
      decimals="2"
      id="ixv-5467"
      unitRef="uref_1680085804">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="cref_623090204"
      decimals="-3"
      id="ixv-5468"
      unitRef="uref_623090204">4000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#fc_485659790"
          xlink:label="fc_485659790"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_624161538"
          xlink:label="fc_624161538"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1439374755"
          xlink:label="fc_1439374755"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_40832969"
          xlink:label="fc_40832969"
          xlink:type="locator"/>
        <link:footnote id="fref_1795325142" xlink:label="fref_1795325142" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively adjusted to give effect to the reverse share split, see also note 6.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_485659790"
          xlink:to="fref_1795325142"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_624161538"
          xlink:to="fref_1795325142"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1439374755"
          xlink:to="fref_1795325142"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_40832969"
          xlink:to="fref_1795325142"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_1080289311"
          xlink:label="fc_1080289311"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_26548218"
          xlink:label="fc_26548218"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1961081762"
          xlink:label="fc_1961081762"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_464583565"
          xlink:label="fc_464583565"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_507776425"
          xlink:label="fc_507776425"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_117223515"
          xlink:label="fc_117223515"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1197433180"
          xlink:label="fc_1197433180"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1036898106"
          xlink:label="fc_1036898106"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1507442036"
          xlink:label="fc_1507442036"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_659933444"
          xlink:label="fc_659933444"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_912825080"
          xlink:label="fc_912825080"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1977624787"
          xlink:label="fc_1977624787"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_284679322"
          xlink:label="fc_284679322"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_317108046"
          xlink:label="fc_317108046"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_40836862"
          xlink:label="fc_40836862"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1321253939"
          xlink:label="fc_1321253939"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_409840626"
          xlink:label="fc_409840626"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1845223154"
          xlink:label="fc_1845223154"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1802582590"
          xlink:label="fc_1802582590"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_852029009"
          xlink:label="fc_852029009"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_309435350"
          xlink:label="fc_309435350"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1526346197"
          xlink:label="fc_1526346197"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_254025928"
          xlink:label="fc_254025928"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_336050472"
          xlink:label="fc_336050472"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1575155540"
          xlink:label="fc_1575155540"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1313348637"
          xlink:label="fc_1313348637"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1156932951"
          xlink:label="fc_1156932951"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_600411129"
          xlink:label="fc_600411129"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1638807315"
          xlink:label="fc_1638807315"
          xlink:type="locator"/>
        <link:footnote id="fref_1298989339" xlink:label="fref_1298989339" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively adjusted to give effect to the reverse share split, see also note 6.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1080289311"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_26548218"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1961081762"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_464583565"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_507776425"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_117223515"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1197433180"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1036898106"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1507442036"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_659933444"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_912825080"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1977624787"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_284679322"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_317108046"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_40836862"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1321253939"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_409840626"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1845223154"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1802582590"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_852029009"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_309435350"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1526346197"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_254025928"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_336050472"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1575155540"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1313348637"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1156932951"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_600411129"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1638807315"
          xlink:to="fref_1298989339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_159356048"
          xlink:label="fc_159356048"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_709383207"
          xlink:label="fc_709383207"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1307329754"
          xlink:label="fc_1307329754"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1789321536"
          xlink:label="fc_1789321536"
          xlink:type="locator"/>
        <link:footnote id="fref_589796204" xlink:label="fref_589796204" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively adjusted to give effect to the reverse share split, see also note 6.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_159356048"
          xlink:to="fref_589796204"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_709383207"
          xlink:to="fref_589796204"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1307329754"
          xlink:to="fref_589796204"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1789321536"
          xlink:to="fref_589796204"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
